AB382

Nevada AB382 expands insurance coverage for biomarker testing to include any testing supported by medical and scientific evidence, regardless of.

Nevada AB382 amends existing law to require public and private health plans to cover biomarker testing when supported by medical and scientific evidence, without the previous requirement that the testing be medically necessary. This change applies to the diagnosis, treatment, management, and ongoing monitoring of any medical condition or disease. The bill also mandates that insurers and health care providers establish clear processes for requesting exceptions or appealing denials of coverage for biomarker testing. The changes take effect on January 1, 2026.